ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GSK has acquired Elsie Biotechnologies, an oligonucleotide therapeutics company, in a deal worth up to $50 million. Oligo therapy aims to modulate gene expression by binding a small strand of DNA or RNA onto longer RNA strands, to achieve effects that are not attainable with existing drugs. The companies began a research partnership in July 2023 to develop Elsie’s oligo drug discovery platform, which GSK licensed earlier this year. GSK says it is developing oligo therapeutics to treat chronic hepatitis B and steatotic liver disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter